Imvax
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
170 S Independence Mall W Ste 440W, Phil...Phone Number
(267) 900-4110Website
www.imvax.comRevenue
$10.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Imvax
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax's portfolio includes several programs designed to stimulate a patient's immune system against the entire antigen signature of their tumor. Imvax's most advanced program is IGV-001 for the treatment of glioblastoma.Explore more
Imvax Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imvax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Imvax
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Imvax has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Imvax has new funding data
Click to see if Imvax had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Imvax recently announced quarterly report
Product Launch: Get notified when Imvax launches new products
Check out if Imvax is spiking on competitors!
Imvax, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Imvax
Find 2 more new buyers
Compare Similar Companies to Imvax
Compare insights from companies similar to Imvax, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Imvax is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Imvax is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Imvax.
Imvax financials insights
Gather financial insights about Imvax, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Unspecified
$14.7M
2019
Series A
$15M
Series B
$25M
2020
Series C
$112M
2025
Other Financing Round
$29M
Imvax Tech Stack
A closer look at the technologies used by Imvax
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Executive Moves, Board of Directors
Person-Based
Funding
Funding
Imvax News & Media
Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Phase 2b Trial of IGV-001 in Newly Diagnosed Glioblastoma
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc. today announced the closing of a $29 million financing round from existing investors.Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc. today announced an oral presentation and two poster presentations at the 2024 SNO Annual Meeting in Houston, Texas.Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the completion of enrollment in its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM). IGV-001 is derived from Imvax’s proprietary Goldspire™ immuno-oncology platform, which is designed to use a patient’s own tumor cells to induce a broad anEBCI Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study
The End Brain Cancer Initiative (EBCI) Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study REDMOND, WA, UNITED STATES, January 16, 2024 /EINPresswire.com/ -- The End Brain Cancer Initiative (EBCI) Brings …
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Imvax
Sign Up For FreeTo access detailed company insights
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax's portfolio includes several programs designed to stimulate a patient's immune system against the entire antigen signature of their tumor. Imvax's most advanc... Read More
